Topics

Clinical Trials About "Efficacy and Safety Study of Lu AA21004 in Adults With Major Depressive Disorder" RSS

06:11 EST 29th January 2020 | BioPortfolio

We list hundreds of Clinical Trials about "Efficacy and Safety Study of Lu AA21004 in Adults With Major Depressive Disorder" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Efficacy and Safety Study of Lu AA21004 in Adults With Major Depressive Disorder" on BioPortfolio

We have published hundreds of Efficacy and Safety Study of Lu AA21004 in Adults With Major Depressive Disorder news stories on BioPortfolio along with dozens of Efficacy and Safety Study of Lu AA21004 in Adults With Major Depressive Disorder Clinical Trials and PubMed Articles about Efficacy and Safety Study of Lu AA21004 in Adults With Major Depressive Disorder for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Efficacy and Safety Study of Lu AA21004 in Adults With Major Depressive Disorder Companies in our database. You can also find out about relevant Efficacy and Safety Study of Lu AA21004 in Adults With Major Depressive Disorder Drugs and Medications on this site too.

Showing "Efficacy Safety Study AA21004 Adults With Major Depressive" Clinical Trials 1–25 of 54,000+

Extremely Relevant

Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder

The purpose of this study is to determine the effectiveness and safety of Lu AA21004, once daily (QD), in patients with Major Depressive Disorder.


Efficacy and Safety of Lu AA21004 in Acute Treatment of Major Depressive Disorder

The purpose of the study is to evaluate the efficacy and the tolerability of three fixed doses of Lu AA21004 in order to establish the appropriate clinical effective dose range in the treatment of Major Depressive Disorder.

Efficacy and Safety of Lu AA21004 in the Treatment of Subjects With Major Depressive Disorder

The purpose of this study is to determine the efficacy and safety of Lu AA21004, once daily (QD), in adults with major depressive disorder.


Efficacy and Safety Study of Lu AA21004 in Adults With Major Depressive Disorder

The purpose of this study is to evaluate the efficacy of Lu AA21004, once daily (QD), compared with placebo in adults with major depressive disorder.

Safety and Efficacy of Lu AA21004 in Adults With Major Depressive Disorder

The purpose of this study is to evaluate the efficacy, safety and tolerability of Lu AA21004, once daily (QD), compared with placebo in adults with major depressive disorder.

Efficacy and Safety of Lu AA21004 in Treating Adult Subjects With Major Depressive Disorder

The purpose of this study is to determine the efficacy and safety of once daily (QD) Lu AA21004 in adults with major depressive disorder.

Efficacy and Safety of Lu AA21004 in Acute Treatment of Major Depressive Disorder

The purpose of the study is to evaluate the efficacy and the safety of two fixed doses of Lu AA21004 in the treatment of Major Depressive Disorder.

Efficacy and Safety of Lu AA21004 in Acute Treatment of Major Depressive Disorder

The purpose of the study is to evaluate the efficacy and the tolerability of two fixed doses of Lu AA21004 in the acute treatment of Major Depressive Disorder.

Efficacy of Lu AA21004 in the Prevention of Relapse of Major Depressive Episodes

This study will evaluate the efficacy of Lu AA21004 in the prevention of relapse of major depressive episodes in patients who responded to open-label treatment with Lu AA21004.

Long-Term Study of Lu AA21004 in Patients With Major Depressive Disorder

The purpose of the study is to evaluate long-term safety and tolerability of Lu AA21004 over a period of 52 weeks in patients with Major Depressive Disorder having completed 6-week acute treatment.

Long-term Safety Study of Lu AA21004 in Patients With Major Depressive Disorder

The purpose of the study is to evaluate long-term safety and tolerability of Lu AA21004 over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 8-week acute treatment.

Efficacy and Safety of Lu AA21004 in Acute Treatment of Major Depressive Disorder in Elderly Patients

To assess the efficacy of Lu AA21004 (5mg daily) versus placebo in the acute treatment of depression by means of the change from baseline in the 24-item Hamilton Depression Scale total score after 8 weeks of double-blind treatment in elderly patients.

Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries

This study will be conducted with the aim of investigating the efficacy, safety and tolerability of 10 mg/day Vortioxetine in Asian patients compared to an approved active comparator (venlafaxine extended release 150 mg/day).

Efficacy and Safety of Lu AA21004 in Treating Generalized Anxiety Disorder

The purpose of this study is to evaluate the safety and efficacy of 2.5 mg and 10 mg of Lu AA21004, once daily (QD), in adults with generalized anxiety disorder

Efficacy and Safety of Lu AA21004 for Treatment of Generalized Anxiety Disorder in Adults.

The purpose of this study is to evaluate the efficacy and safety of Lu AA21004, once daily (QD), in adults with Generalized Anxiety Disorders.

An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder

A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in Patients with Major Depressive Disorder (MDD)

An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder

A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in Patients with Major Depressive Disorder (MDD)

Relapse-prevention Study With Lu AA21004 in Patients With Generalized Anxiety Disorder

The study will evaluate the long-term maintenance of efficacy of Lu AA21004 in patients with Generalized Anxiety Disorder (GAD) who responded to acute treatment with Lu AA21004.

An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder

A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Radafaxine in Patients with Major Depressive Disorder (MDD)

A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

The primary purpose is to study the efficacy, safety, and tolerability of LY2216684 as an adjunctive treatment for patients with major depressive disorder (MDD), who were identified as partial responders to an adequate course of treatment with a selective serotonin reuptake inhibitor (SSRI) (as defined by history).

A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets

The purpose of this study is to evaluate the bioequivalence of a single oral administration of a Lu AA21004 20 mg tablet in comparison with two of Lu AA21004 10 mg tablets in Japanese healthy adult participants.

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.

A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder

MIN-117C03 is a 6-week, 3-arm, randomized, double-blind, placebo-controlled study to investigate the safety and efficacy of MIN-117 in male and female patients with Major Depressive Disorder, aged 18 to 65 years. Approximately 324 patients will be randomly assigned to 1 of 3 treatment arms, including placebo, 5.0 mg MIN-117, or 2.5 mg MIN-117 in a 2:1:1 ratio.

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Subjects With Major Depressive Disorder

This is a study with an open-label (OL) phase followed by a randomized, double-blind (DB), placebo-controlled phase to assess efficacy and safety of SAGE-217 on relapse prevention in adults with major depressive disorder.

Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder

Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults. This study is designed to evaluate the efficacy and safety of a fixed-dose escitalopram combination relative to its component monotherapies and to placebo in patients with major depressive disorder.


More From BioPortfolio on "Efficacy and Safety Study of Lu AA21004 in Adults With Major Depressive Disorder"

Quick Search